Literature DB >> 28035472

Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia.

Hans-Gert Bernstein1, Susan Müller2, Hendrik Dobrowolny2, Carmen Wolke3, Uwe Lendeckel3, Alicja Bukowska4, Gerburg Keilhoff5, Axel Becker6, Kurt Trübner7, Johann Steiner2, Bernhard Bogerts2.   

Abstract

The vasopressin- and oxytocin-degrading enzyme insulin-regulated aminopeptidase (IRAP) is expressed in various organs including the brain. However, knowledge about its presence in human hypothalamus is fragmentary. Functionally, for a number of reasons (genetic linkage, hydrolysis of oxytocin and vasopressin, its role as angiotensin IV receptor in learning and memory and others) IRAP might play a role in schizophrenia. We studied the regional and cellular localization of IRAP in normal human brain with special emphasis on the hypothalamus and determined numerical densities of IRAP-expressing cells in the paraventricular, supraoptic and suprachiasmatic nuclei in schizophrenia patients and controls. By using immunohistochemistry and Western blot analysis, IRAP was immunolocalized in postmortem human brains. Cell countings were performed to estimate numbers and numerical densities of IRAP immunoreactive hypothalamic neurons in schizophrenia patients and control cases. Shape, size and regional distribution of IRAP-expressing cells, as well the lack of co-localization with the glia marker glutamine synthetase, show that IRAP is expressed in neurons. IRAP immunoreactive cells were observed in the hippocampal formation, cerebral cortex, thalamus, amygdala and, abundantly, hypothalamus. Double labeling experiments (IRAP and oxytocin/neurophysin 1, IRAP with vasopressin/neurophysin 2) revealed that IRAP is present in oxytocinergic and in vasopressinergic neurons. In schizophrenia patients, the numerical density of IRAP-expressing neurons in the paraventricular and the suprachiasmatic nuclei is significantly reduced, which might be associated with the reduction in neurophysin-containing neurons in these nuclei in schizophrenia. The pathophysiological role of lowered hypothalamic IRAP expression in schizophrenia remains to be established.

Entities:  

Keywords:  Human brain; Hypothalamus; Immunohistochemistry; Insulin-regulated aminopeptidase; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 28035472     DOI: 10.1007/s00406-016-0757-7

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  66 in total

1.  Tissue distribution of CysAP activity and its relationship to blood pressure and water balance.

Authors:  Isabel Prieto; Ana Belén Villarejo; Ana Belén Segarra; Rosemary Wangensteen; Inmaculada Banegas; Marc de Gasparo; Patrick Vanderheyden; Stefan Zorad; Francisco Vives; Manuel Ramírez-Sánchez
Journal:  Life Sci       Date:  2015-05-23       Impact factor: 5.037

Review 2.  The contributions of oxytocin and vasopressin pathway genes to human behavior.

Authors:  Richard P Ebstein; Ariel Knafo; David Mankuta; Soo Hong Chew; Poh San Lai
Journal:  Horm Behav       Date:  2011-12-29       Impact factor: 3.587

3.  Schizophrenia as a possible dysfunction of the suprachiasmatic nucleus.

Authors:  Sinisa M Trbovic
Journal:  Med Hypotheses       Date:  2009-08-05       Impact factor: 1.538

4.  Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase.

Authors:  A L Albiston; S G McDowall; D Matsacos; P Sim; E Clune; T Mustafa; J Lee; F A Mendelsohn; R J Simpson; L M Connolly; S Y Chai
Journal:  J Biol Chem       Date:  2001-11-13       Impact factor: 5.157

Review 5.  Major histocompatibility complex I in brain development and schizophrenia.

Authors:  A Kimberley McAllister
Journal:  Biol Psychiatry       Date:  2013-10-10       Impact factor: 13.382

6.  Distribution of immunoreactive glutamine synthetase in the adult human and mouse brain. Qualitative and quantitative observations with special emphasis on extra-astroglial protein localization.

Authors:  Hans-Gert Bernstein; Jana Bannier; Gabriela Meyer-Lotz; Johann Steiner; Gerburg Keilhoff; Henrik Dobrowolny; Martin Walter; Bernhard Bogerts
Journal:  J Chem Neuroanat       Date:  2014-07-22       Impact factor: 3.052

7.  Binding to and Inhibition of Insulin-Regulated Aminopeptidase by Macrocyclic Disulfides Enhances Spine Density.

Authors:  Shanti Diwakarla; Erik Nylander; Alfhild Grönbladh; Sudarsana Reddy Vanga; Yasmin Shamsudin Khan; Hugo Gutiérrez-de-Terán; Leelee Ng; Vi Pham; Jonas Sävmarker; Thomas Lundbäck; Annika Jenmalm-Jensen; Hanna Andersson; Karin Engen; Ulrika Rosenström; Mats Larhed; Johan Åqvist; Siew Yeen Chai; Mathias Hallberg
Journal:  Mol Pharmacol       Date:  2016-01-14       Impact factor: 4.436

8.  Vasopressin and oxytocin in control of the cardiovascular system.

Authors:  Nina Japundžić-Žigon
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

Review 9.  Local control of striatal dopamine release.

Authors:  Roger Cachope; Joseph F Cheer
Journal:  Front Behav Neurosci       Date:  2014-05-23       Impact factor: 3.558

10.  Genetic modulation of oxytocin sensitivity: a pharmacogenetic approach.

Authors:  F S Chen; R Kumsta; F Dvorak; G Domes; O S Yim; R P Ebstein; M Heinrichs
Journal:  Transl Psychiatry       Date:  2015-10-27       Impact factor: 6.222

View more
  2 in total

1.  Editorial: Physiological, Pathological Roles and Pharmacology of Insulin Regulated Aminopeptidase.

Authors:  Siew Yeen Chai; Hugo Gutiérrez-de-Terán; Efstratios Stratikos
Journal:  Front Mol Biosci       Date:  2021-04-23

2.  NLRP3 Inflammasome Blocking as a Potential Treatment of Central Insulin Resistance in Early-Stage Alzheimer's Disease.

Authors:  Yulia K Komleva; Ilia V Potapenko; Olga L Lopatina; Yana V Gorina; Anatoly Chernykh; Elena D Khilazheva; Alla B Salmina; Anton N Shuvaev
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.